Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Preferred Stock Liabilities (2020)

Bolt Biotherapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $105.3 million for Q4 2020.

  • For Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $105.3 million; the TTM value through Dec 2020 reached $105.3 million, changed N/A, while the annual FY2020 figure was $105.3 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2020 was $105.3 million at Bolt Biotherapeutics, roughly flat from $105.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $105.3 million in Q3 2020 and bottomed at $41.3 million in Q2 2020.